Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, this warning letter was issued to Snyder Mark Drugs Roselle, Inc., operating as Mark Drugs Pharmacy, a retail pharmacy operation. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined, though they likely relate to pharmacy operations, product handling, or regulatory compliance standards. The warning was issued on February 27, 2018, though the specific FDA office responsible and detailed violation count are not specified in the available metadata. To understand the complete regulatory concerns and required corrective actions, the full warning letter text would need to be reviewed.